| Date Filed | Type | Description |
| 09/28/2023 |
8-K
| Quarterly results |
| 08/25/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 08/24/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 08/21/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 08/21/2023 |
SC 13D/A
| Wolf Jeffrey Alan reports a 11.7% stake in NIGHTHAWK BIOSCIENCES, INC. |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/14/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 03/31/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/31/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 03/23/2023 |
8-K
| Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review, Other Events, F... |
| 03/13/2023 |
8-A12B/A
| Form 8-A12B/A - Registration of securities [Section 12(b)]: [Amend] |
| 03/13/2023 |
8-K
| Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Financial Statements and Ex... |
| 02/02/2023 |
8-K
| Quarterly results |
| 01/05/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 12/30/2022 |
SC 13D/A
| Wolf Jeffrey Alan reports a 10.6% stake in NIGHTHAWK BIOSCIENCES, INC. |
| 12/09/2022 |
8-K
| Quarterly results |
| 12/09/2022 |
4
| Wolf Jeffrey Alan (CEO) has filed a Form 4 on NightHawk Biosciences, Inc.|
Txns:
| Granted 2,843,137 options to buy
@ $1.02, valued at
$2.9M
|
|
| 12/09/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/09/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/09/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/09/2022 |
4
| MONAHAN JOHN J (Director) has filed a Form 4 on NightHawk Biosciences, Inc.|
Txns:
| Granted 101,960 options to buy
@ $1.02, valued at
$104k
|
|
| 11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/14/2022 |
8-K
| Quarterly results |
| 10/03/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 09/16/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/22/2022 |
8-K
| Quarterly results |
| 08/10/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/10/2022 |
8-K
| Quarterly results |
| 07/28/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 06/06/2022 |
8-K/A
| Quarterly results |
| 05/16/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/16/2022 |
8-K
| Quarterly results |
| 05/03/2022 |
8-K
| Quarterly results |
| 04/25/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
|